Synthesis and biological activity of salinomycin conjugates with floxuridine

European Journal of Medicinal Chemistry

Volumn 93, Issue , 2015, Pages 33-41

  Huczyński, Adam ^a   Antoszczak, Michał ^a   Kleczewska, Natalia ^a   Lewowska, Marta ^a   Maj, Ewa ^b   Stefańska, Joanna ^c   Wietrzyk, Joanna ^b   Janczak, Jan ^d   Celewicz, Lech ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d INSTITUTE OF LOW TEMPERATURE AND STRUCTURE RESEARCH   (Poland)

Author keywords

Antibacterial activity; Anticancer activity; Conjugation; Hybrid compound

Indexed keywords

3' AZIDO 2' ,3' DIDEOXY 5 FLUOROURIDINE; AMIDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CUPROUS ION; DOXORUBICIN; ESTER; FLOXURIDINE DERIVATIVE; FLUOROURACIL; SALINOMYCIN DERIVATIVE; SALINOMYCIN PROPARGYL AMIDE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; ANTIINFECTIVE AGENT; FLOXURIDINE; PYRAN DERIVATIVE; SALINOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOLOGICAL ACTIVITY; CANCER CELL LINE; CANCER STEM CELL; CATALYSIS; CHEMICAL STRUCTURE; CLICK CHEMISTRY; CONJUGATE; CONJUGATION; CYCLOADDITION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE ACTIVITY RELATION; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; SYNTHESIS; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; FLOXURIDINE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR STRUCTURE; PYRANS; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922231172     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.01.045     Document Type: Article

References (54)

1. J.F. Lutz, Z. Zarafshani, Efficient construction of therapeutics, bioconjugates, biomaterial and bioactive surfaces using azide-alkyne "click" chemistry, Adv. Drug Deliv. Rev. 60 (2008) 958-970.
2. T.H. Senanayake, G. Warren, S.V. Vinogradov, Novel anticancer polymeric conjugates of activated nucleoside analogues, Bioconjug. Chem. 22 (2011) 1983-1993.
3. K.A. Papavassiliou, A.G. Papavassiliou, Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment, Exp. Opin. Invest. Drugs 23 (2014) 291-294.
4. T. Robak, P. Robak, Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias, Curr. Pharm. Des. 18 (2012) 3373-3388.
5. S.W. Hung, H.R. Mody, R. Govindarajan, Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge, Cancer Lett. 320 (2012) 138-149.
6. E. De Clercq, Ten paths to the discovery of antivirally active nucleoside and nucleotide analogues, Nucleos. Nucleot. Nucl. 31 (2012) 339-352.
7. W.A. El-Sayed, F.A. El-Essawy, O.M. Ali, B.S. Nasr, M.M. Abdalla, A.A.H. Abdel-Rahman, Synthesis and antiviral evaluation of new 2,5-disubstituted 1,3,4-oxadiazole derivatives and their acyclic nucleoside analogues, Mon. Chem. 141 (2010) 1021-1028.
8. V.P. Costantini, T. Whitaker, L. Barclay, D. Lee, T.R. McBrayer, R.F. Shinazi, J. Vinjé, Antiviral activity of nucleoside analogues against norovirus, Antivir. Ther. 17 (2012) 981-991.
9. D.B. Longley, D.P. Harkin, P.G. Johnston, 5-Fluorouracil: mechanisms of action and clinical strategies, Nat. Rev. Cancer 3 (2003) 330-338.
10. R.B. Diasio, B.E. Harris, Clinical pharmacology of 5-fluorouracil, Clin. Pharmacokinet. 16 (1989) 215-237.
11. G. Bocci, C. Barbara, F. Vannozzi, A. Di Paolo, A. Melosi, G. Barsanti, G. Allegrini, A. Falcone, M. Del Tacca, R. Danesi, A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity, Clin. Pharm. Ther. 80 (2006) 384-395.
12. M. Boisdron-Celle, G. Remaud, S. Traore, A.L. Poirier, L. Gamelin, A. Morel, E. Gamelin, 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency, Cancer Lett. 249 (2007) 271-282.
13. P. Samaras, S. Breitenstein, S.R. Haile, F. Stenner-Liewen, S. Heinrich, J. Feilchenfeldt, C. Renner, A. Knuth, B.C. Pestalozzi, P.A. Clavien, Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases, Ann. Surg. Oncol. 18 (2011) 1924-1931.
14. D.G. Power, N.E. Kemeny, The role of floxuridine in metastatic liver disease, Mol. Cancer Ther. 8 (2009) 1015-1025.
15. J.L. Grem, 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development, Invest. New. Drugs 18 (2000) 299-313.
16. C.P. Landowski, B.S. Vig, X. Song, G.L. Amidon, Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs, Mol. Cancer Ther. 4 (2005) 659-667.
17. G.M. Cragg, P.G. Grothaus, D.J. Newman, Impact of natural products on developing new anti-cancer agents, Chem. Rev. 109 (2009) 3012-3043.
18. A. Bhanot, R. Sharma, M.N. Noolvi, Natural sources as potential anti-cancer agents: a review, Int. J. Phytomedicine 3 (2011) 9-26.
19. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, E.S. Lander, Cell 138 (2009) 645-659.
20. L. Han, S. Shi, T. Gong, Z. Zhang, X. Sun, Cancer stem cells: therapeutic implications and perspectives in cancer therapy, Acta Pharm. Sin. B 3 (2013) 65-75.
21. S. Zhou, F. Wang, E.T. Wong, E. Fonkem, T.C. Hsich, J.M. Wu, E. Wu, Salinomycin: a novel anti-cancer agent with known anti-coccidial activities, Curr. Med. Chem. 20 (2013) 4095-4101.
22. F. Wang, L. He, W.Q. Dai, Y.P. Xu, D. Wu, C.L. Lin, S.M. Wu, P. Cheng, Y. Zhang, M. Shen, C.F. Wang, J. Lu, Y.Q. Zhou, X.F. Xu, L. Xu, C.Y. Guo, Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo, PLoS ONE 7 (2012) article number: e50638.
23. T. Lieke, W. Ramackers, S. Bergmann, J. Klempnauer, M. Winkler, J. Klose, Impact of salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro, BMC Cancer 12 (2012) article number: 466.
24. high stem-like cells on gastric cancer, Biomed. Pharmacother. 65 (2011) 509-515.
25. Q.L. Tang, Z.Q. Zhao, J.C. Li, Y. Liang, J.Q. Yin, C.Y. Zou, X.B. Xie, Y.X. Zeng, J.N. Shen, T. Kang, J. Wang, Salinomycin inhibits osteosarcoma by targeting its tumor stem cells, Cancer Lett. 311 (2011) 113-121.
26. A. Huczyński, J. Janczak, M. Antoszczak, J. Stefańska, B. Brzezinski, X-ray, FT-IR, NMR and PM5 structural studies and antibacterial activity of unexpectedly stable salinomycin-benzotriazole intermediate ester, J. Mol. Struct. 1022 (2012) 197-203.
27. A. Huczyński, J. Janczak, J. Stefańska, M. Antoszczak, B. Brzezinski, Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic - salinomycin, Bioorg. Med. Chem. Lett. 22 (2012) 4697-4702.
28. A. Huczyński, J. Janczak, M. Antoszczak, J. Wietrzyk, E. Maj, B. Brzezinski, Antiproliferative activity of salinomycin and its derivatives, Bioorg. Med. Chem. Lett. 22 (2012) 7146-7150.
29. M. Antoszczak, E. Maj, J. Stefańska, J. Wietrzyk, J. Janczak, B. Brzezinski, A. Huczyński, Synthesis, antiproliferative and antibacterial activity of new amides of salinomycin, Bioorg. Med. Chem. Lett. 24 (2014) 1724-1729.
30. M. Antoszczak, K. Popiel, J. Stefańska, J. Wietrzyk, E. Maj, J. Janczak, G. Michalska, B. Brzezinski, A. Huczyński, Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic - salinomycin, Eur. J. Med. Chem. 76 (2014) 435-444.
31. B. Borgström, X. Huang, M. Pošta, C. Hegardt, S. Oredsson, D. Strand, Synthetic modification of salinomycin: selective O-acylation and biological evaluation, Chem. Commun. 49 (2013) 9944-9946.
32. C. Naujokat, R. Steinhart, Salinomycin as a drug for targeting human cancer stem cells, J. Biomed. Biotechnol. 2012 (2012) article ID 950658.
33. F. Wang, W. Dai, Y. Wang, M. Shen, K. Chen, P. Cheng, Y. Zhang, C. Wang, J. Li, Y. Zheng, J. Lu, J. Yang, R. Zhu, H. Zhang, Y. Zhou, L. Xu, C. Guo, The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma, PLoS ONE 9 (2014) article number e97414.
34. M. Lewandowska, P. Ruszkowski, D. Baraniak, A. Czarnecka, N. Kleczewska, L. Celewicz, Synthesis of 3′-azido-2′,3′-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity, Eur. J. Med. Chem. 67 (2013) 188-195.
35. J.H. Hooijberg, N.A. De Vries, G.J.L. Kaspers, R. Pieters, G. Jansen, G.J. Peters, Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment, Cancer Chem. Pharm. 58 (2006) 1-12.
36. M. Broggini, M. Grandi, P. Ubezio, C. Geroni, F.C. Giuliani, M. D'Incalci, Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline, Biochem. Pharmacol. 37 (1988) 4423-4431.
37. T. McGrath, C. Latoud, S.T. Arnold, A.R. Safa, R.L. Felsted, M.S. Center, Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression, Biochem. Pharmacol. 38 (1989) 3611-3619.
38. S. Temraz, D. Mukherji, R. Alameddine, Shamseddine, Methods of overcoming treatment resistance in colorectal cancer, Crit. Rev. Oncol. Hematol. 89 (2014) 217-230.
39. E. Paldino, V. Tesori, P. Casalbore, A. Gasbarrini, M.A. Puglisi, Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells? Biomed. Res. Int. 2014 (2014) art id: 859871.
40. B. Drewinko, L.Y. Yang, B. Barlogie, M. Romsdahl, M. Meistrich, M.A. Malahy, B. Giovanella, Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line, J. Natl. Cancer Inst. 61 (1978) 75-83.
41. B.H. Tom, L.P. Rutzky, M.M. Jakstys, R. Oyasu, C.I. Kaye, B.D. Kahan, Human colonic adenocarcinoma cells. I. Establishment and description of a new line, Vitro 12 (1976) 180-191.
42. A. Habicht, M. Lindauer, P. Galmbacher, W. Rudy, J. Gebert, H.K. Schackert, S.C. Meuer, U. Moebius, Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro, Eur. J. Cancer 31A (1995) 2396-2402.
43. W.G. Harker, W. Slade, P.S. Meltzer, J.M. Trent, Multidrug resistance in mitoxantrone HL leukemia cells in the absence of Pglycoprotein overexpression, Cancer Res. 49 (1989) 4542-4549.
44. B.S. Vig, P.J. Lorenzi, S. Mittal, C.P. Landowski, H.C. Shin, H.I. Mosberg, J.M. Hilfinger, G.L. Amidon, Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry and site of esterification on the rate of hydrolysis, Pharm. Res. 20 (2003) 1381-1388.
45. C.P. Landowski, P.L. Lorenzi, X. Song, G.L. Amidon, Nucleoside ester prodrug substrate specificity of liver carboxylesterase, J. Pharmacol. Exp. Ther. 316 (2006) 572-580.
46. M. Rooseboom, J.N. Commandeur, N.P. Vermeulen, Enzyme catalyzed activation of anticancer prodrugs, Pharmacol. Rev. 56 (2004) 53-102.
47. A.L. Simpĺcio, J.M. Clancy, J.F. Gilmer, Prodrugs for amines, Molecules 13 (2008) 519-547.
48. CrysAlis CCD and CrysAlis RED, V. 1.171.33.42, Oxford Diffraction Poland, Wrocław, Poland, 2009.
49. G.M. Sheldrick, Acta Cryst. A64 (2008) 112-122.
50. K. Brandenburg, H. Putz, Diamond v. 3.1, Crystal Impact GbR, Bonn, Germany, 2008.
51. D.S. Pedersen, C. Rosenbohm, Dry column vacuum chromatography, Synthesis 16 (2001) 2431-2434.
52. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard M2-A-9, CLSI, Wayne, Pa. USA, 2006.
53. Clinical and Laboratory Standards Institute, Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Proposed Guideline, CLSI document M44-P, CLSI, Wayne, Pa. USA, 2003.
54. Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard M7-A-7, CLSI, Wayne, Pa. USA, 2006.